Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors, Excluding Breast Cancer
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT01596647
- Locations
- 🇺🇸
Comprehensive Cancer Centers, Las Vegas, Nevada, United States
🇺🇸University of Kansas Cancer Center Medical Center, Kansas City, Kansas, United States
🇺🇸Henry Ford Hospital Henry Ford, Detroit, Michigan, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 209
- Registration Number
- NCT01596712
- Locations
- 🇯🇵
Novartis Investigative Site, Sagamihara, Kanagawa, Japan
Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)
Phase 2
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT01596062
- Locations
- 🇫🇷
Novartis Investigative Site, Tours Cedex, France
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT01594957
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT01595009
- Locations
- 🇩🇪
Novartis Investigative Site, Weiden, Germany
A Prospective, Open Label Study of CERtican in KIdney Transplantation
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01594268
- Locations
- 🇰🇷
Novartis Investigative Site, Suwon, Korea, Republic of
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
Phase 2
Completed
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Interventions
- Procedure: Panretinal laser photocoagulation
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT01594281
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
Phase 2
Completed
- Conditions
- Non Familial Chylocmicronemia Syndrome (Non-FCS)
- Interventions
- Drug: Placebo of LCQ908Drug: Placebo of fish oil
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01594983
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
CAEB071 Thorough QTc Study in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT01594255
- Locations
- 🇺🇸
Novartis Investigational Site, Austin, Texas, United States
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
Phase 3
Withdrawn
- Conditions
- Acute Gouty Arthritis
- Interventions
- Drug: Triamcinelone acetonide
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01593527
© Copyright 2025. All Rights Reserved by MedPath